European Commission President Ursula von der Leyen wants the EU to focus on vaccines based on so-called mRNA technologies, such as those from pharmaceuticals Pfizer / BioNTech and Moderna, when purchasing corona vaccines.
She says the EU may need new vaccines for extra protection against the coronavirus after people have already been vaccinated or to fight new variants of the virus.
The German underlined that this does not mean that future contracts will not be signed with producers who do not use mRNA technology, such as AstraZeneca and Johnson & Johnson for the Janssen vaccine.
Possible rare side effects with blood clots after vaccination with vaccines from these two manufacturers are currently under investigation.